-
Je něco špatně v tomto záznamu ?
Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
F. Cibulcik, J. Benetin, E. Kurca, M. Grofik, M. Dvorak, D. Richter, V. Donath, J. Kothaj, M. Minar, P. Valkovic
Jazyk angličtina Země Česko
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
27108605
DOI
10.5507/bp.2016.023
Knihovny.cz E-zdroje
- MeSH
- analýza rozptylu MeSH
- antiparkinsonika aplikace a dávkování MeSH
- indany aplikace a dávkování MeSH
- kvalita života MeSH
- lidé MeSH
- neurologické poruchy chůze farmakoterapie MeSH
- Parkinsonova nemoc farmakoterapie MeSH
- průzkumy a dotazníky MeSH
- rozvrh dávkování léků MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
AIMS: Freezing of gait is a disabling symptom in advanced Parkinson's disease. Positive effects have been suggested with MAO-B inhibitors. We report on an open label clinical study on the efficacy of rasagiline as add-on therapy on freezing of gait and quality of life in patients with Parkinson's disease. METHODS: Forty two patients with freezing of gait were treated with 1 mg rasagiline daily as an add-on therapy. Patients were assessed at baseline and after 1, 2 and 3 months of treatment. Freezing of gait severity was assessed using the Freezing of Gait Questionnaire, motor impairment by the modified MDS UPDRS part III, and quality of life using the PDQ-39 questionnaire. RESULTS: Patients treated with rasagiline had a statistically significant decrease in FoG-Q score and modified MDS UPDRS score after 1, 2 and 3 months of therapy. A moderately strong (r = 0.686, P = 0.002) correlation between the effects on mobility and freezing of gait was found. We also observed a statistically significant improvement in global QoL and in the subscales mobility, ADL, stigma and bodily discomfort in patients after 3 months of rasagiline therapy. A significant correlation (r = 0.570, P = 0.02) between baseline FoG-Q score and the baseline score for the PDQ Mobility subscale was found. CONCLUSION: In our study rasagiline as add-on antiparkinsonian therapy significantly improved mobility, freezing of gait and quality of life. The positive effect on freezing of gait appears to be related to improvement of mobility.
2nd Department of Neurology Faculty of Medicine Comenius University in Bratislava Slovak Republic
Department of Neurology Hospital Spisska Nova Ves Slovak Republic
Department of Neurology Slovak Health University Roosevelt Hospital Banska Bystrica Slovak Republic
Department of Neurology University Hospital Bratislava Slovak Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17016699
- 003
- CZ-PrNML
- 005
- 20170519133914.0
- 007
- ta
- 008
- 170516s2016 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2016.023 $2 doi
- 035 __
- $a (PubMed)27108605
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Cibulčík, František $u Department of Neurology, Faculty of Medicine, Slovak Medical University in Bratislava and University Hospital Bratislava, Slovak Republic $7 xx0106477
- 245 10
- $a Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study / $c F. Cibulcik, J. Benetin, E. Kurca, M. Grofik, M. Dvorak, D. Richter, V. Donath, J. Kothaj, M. Minar, P. Valkovic
- 520 9_
- $a AIMS: Freezing of gait is a disabling symptom in advanced Parkinson's disease. Positive effects have been suggested with MAO-B inhibitors. We report on an open label clinical study on the efficacy of rasagiline as add-on therapy on freezing of gait and quality of life in patients with Parkinson's disease. METHODS: Forty two patients with freezing of gait were treated with 1 mg rasagiline daily as an add-on therapy. Patients were assessed at baseline and after 1, 2 and 3 months of treatment. Freezing of gait severity was assessed using the Freezing of Gait Questionnaire, motor impairment by the modified MDS UPDRS part III, and quality of life using the PDQ-39 questionnaire. RESULTS: Patients treated with rasagiline had a statistically significant decrease in FoG-Q score and modified MDS UPDRS score after 1, 2 and 3 months of therapy. A moderately strong (r = 0.686, P = 0.002) correlation between the effects on mobility and freezing of gait was found. We also observed a statistically significant improvement in global QoL and in the subscales mobility, ADL, stigma and bodily discomfort in patients after 3 months of rasagiline therapy. A significant correlation (r = 0.570, P = 0.02) between baseline FoG-Q score and the baseline score for the PDQ Mobility subscale was found. CONCLUSION: In our study rasagiline as add-on antiparkinsonian therapy significantly improved mobility, freezing of gait and quality of life. The positive effect on freezing of gait appears to be related to improvement of mobility.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a antiparkinsonika $x aplikace a dávkování $7 D000978
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a neurologické poruchy chůze $x farmakoterapie $7 D020233
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indany $x aplikace a dávkování $7 D007189
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a Parkinsonova nemoc $x farmakoterapie $7 D010300
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Benetin, Ján $u Department of Neurology, Faculty of Medicine, Slovak Medical University in Bratislava and University Hospital Bratislava, Slovak Republic $7 xx0140825
- 700 1_
- $a Kurča, Egon, $u Department of Neurology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin and University Hospital Martin, Slovak Republic $d 1964- $7 nlk20050162662
- 700 1_
- $a Grofik, Milan $u Department of Neurology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin and University Hospital Martin, Slovak Republic $7 xx0138028
- 700 1_
- $a Dvorák, Miloslav $u Department of Neurology, Hospital Spisska Nova Ves, Slovak Republic $7 xx0244020
- 700 1_
- $a Richter, Denis $u Department of Neurology, University Hospital Bratislava, Slovak Republic $7 _AN029956
- 700 1_
- $a Donáth, Vladimír, $u Department of Neurology, Slovak Health University, Roosevelt Hospital Banska Bystrica, Slovak Republic $d 1949- $7 xx0063678
- 700 1_
- $a Kothaj, J. $u Department of Neurology, Slovak Health University, Roosevelt Hospital Banska Bystrica, Slovak Republic $7 _AN044105
- 700 1_
- $a Minár, Michal $u Second Department of Neurology, Faculty of Medicine, Comenius University in Bratislava, Slovak Republic $7 xx0233961
- 700 1_
- $a Valkovič, Peter $u Second Department of Neurology, Faculty of Medicine, Comenius University in Bratislava, Slovak Republic $7 xx0107011
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 4 (2016), s. 549-552
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170516 $b ABA008
- 991 __
- $a 20170517142121 $b ABA008
- 999 __
- $a ok $b bmc $g 1205839 $s 977508
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 160 $c 4 $d 549-552 $e 20160421 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170516